| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| salbutamol sulfate | Inhalation, conventional | 3 mg | Current | Unavailable | Manufacturing | 22/06/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Anticipated | Available | Manufacturing | 22/06/2025 |
| isotretinoin | Capsule, soft | 20 mg | Anticipated | Available | Manufacturing | 22/06/2025 |
| lamotrigine | Tablet, chewable | 200 mg | Anticipated | Available | Manufacturing | 22/06/2025 |
| bupivacaine hydrochloride | Injection, solution | 2.5 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 20/06/2025 |
| trandolapril | Capsule | 4 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 20/06/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Manufacturing | 20/06/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 20/06/2025 |
| ciclesonide | Spray, nasal | 50 microgram/actuation | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 20/06/2025 |
| levetiracetam | Tablet, film coated | 1000 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 20/06/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Current | Limited Availability | Manufacturing | 20/06/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Anticipated | Available | Manufacturing | 20/06/2025 |
| finasteride | Tablet, film coated | 1 mg | Current | Limited Availability | Manufacturing | 20/06/2025 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 20/06/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Resolved | Available | Unexpected increase in consumer demand | 20/06/2025 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Current | Unavailable | Unexpected increase in consumer demand | 20/06/2025 |
| norethisterone acetate~estradiol~estradiol | Drug delivery system, transdermal | 2.7 mg~.62 mg~.78 mg | Current | Unavailable | Manufacturing | 20/06/2025 |
| estradiol~norethisterone acetate~estradiol | Drug delivery system, transdermal | .78 mg~4.8 mg~.512 mg | Current | Unavailable | Manufacturing | 20/06/2025 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Limited Availability | Manufacturing | 20/06/2025 |
| bupivacaine hydrochloride | Injection, solution | 1.25 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 20/06/2025 |
| estradiol~norethisterone acetate | Drug delivery system, transdermal | .62 mg~2.7 mg | Current | Unavailable | Manufacturing | 20/06/2025 |
| prazosin hydrochloride | Tablet, uncoated | 1.1 mg | Current | Unavailable | Manufacturing | 20/06/2025 |
| prazosin hydrochloride | Tablet, uncoated | 2.2 mg | Current | Unavailable | Manufacturing | 20/06/2025 |
| prazosin hydrochloride | Tablet, uncoated | 5.5 mg | Current | Unavailable | Manufacturing | 20/06/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Anticipated | Available | Manufacturing | 20/06/2025 |
| bupivacaine hydrochloride monohydrate | Injection, solution | 52.7 mg | Anticipated | Available | Manufacturing | 19/06/2025 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 19/06/2025 |
| mycophenolate mofetil | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 19/06/2025 |
| exemestane | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 19/06/2025 |
| trimethoprim~sulfamethoxazole | Tablet, uncoated | 160 mg~800 mg | Resolved | Available | Manufacturing | 19/06/2025 |
| paracetamol~tramadol hydrochloride | Tablet, film coated | 325 mg~37.5 mg | Resolved | Available | Commercial Changes / Commercial viability | 19/06/2025 |
| capecitabine | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 19/06/2025 |
| cefuroxime axetil | Tablet, film coated | 300.715 mg | Current | Limited Availability | Manufacturing | 19/06/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Current | Limited Availability | Manufacturing | 19/06/2025 |
| mupirocin calcium | Ointment | 21.5 mg/g | Anticipated | Available | Manufacturing | 19/06/2025 |
| estradiol | Drug delivery system, transdermal | .585 mg | Resolved | Available | Manufacturing | 19/06/2025 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Unavailable | Unexpected increase in consumer demand | 19/06/2025 |
| midazolam | Injection, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 19/06/2025 |
| verapamil hydrochloride | Tablet, modified release | 240 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| baclofen | Tablet, uncoated | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 18/06/2025 |
| methylphenidate hydrochloride | Tablet, uncoated | 10 mg | Anticipated | Available | Manufacturing | 18/06/2025 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.82 mg/mL | Resolved | Available | Manufacturing | 18/06/2025 |
| bicalutamide | Tablet, film coated | 50 mg | Anticipated | Available | Unexpected increase in consumer demand | 18/06/2025 |
| vincristine sulfate | Injection, solution | 1 mg/mL | Resolved | Available | Manufacturing | 18/06/2025 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 18/06/2025 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 18/06/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.583 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 41.583 mg~10 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| atomoxetine hydrochloride | Capsule, hard | 45.72 mg | Current | Unavailable | Manufacturing | 18/06/2025 |
| anastrozole | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 18/06/2025 |
| solifenacin succinate | Tablet | 5 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Current | Unavailable | Manufacturing | 18/06/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 10.845 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 18/06/2025 |
| cinacalcet hydrochloride | Tablet, film coated | 99 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| tamoxifen citrate | Tablet | 30.34 mg | Resolved | Available | Manufacturing | 18/06/2025 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 56.69 mg | Current | Unavailable | Manufacturing | 18/06/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Resolved | Available | Manufacturing | 18/06/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.6 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| levothyroxine sodium | Tablet | 75 microgram | Current | Unavailable | Manufacturing | 18/06/2025 |
| dacarbazine | Injection, powder for | 200 mg | Anticipated | Available | Manufacturing | 18/06/2025 |
| nizatidine | Capsule | 150 mg | Current | Limited Availability | Manufacturing | 18/06/2025 |
| calcitonin salmon | Injection, solution | 100 IU/mL | Current | Limited Availability | Commercial Changes / Commercial viability | 17/06/2025 |
| prilocaine~lidocaine | Gel | 42.5 mg~42.5 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 17/06/2025 |
| irinotecan hydrochloride trihydrate | Injection | 20 mg/mL | Discontinued | Unavailable | Manufacturing | 17/06/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Limited Availability | Manufacturing | 17/06/2025 |
| pregabalin | Capsule | 300 mg | Resolved | Available | Manufacturing | 17/06/2025 |
| rifampicin | Capsule | 300 mg | Current | Unavailable | Manufacturing | 17/06/2025 |
| deferasirox | Tablet, film coated | 360 mg | Anticipated | Available | Manufacturing | 17/06/2025 |
| pirfenidone | Tablet | 267 mg | Resolved | Available | Manufacturing | 17/06/2025 |
| thiotepa | Injection, powder for | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 17/06/2025 |
| thiotepa | Injection, powder for | 100 mg | Current | Unavailable | Commercial Changes / Commercial viability | 17/06/2025 |
| thiotepa | Injection, powder for | 400 mg | Current | Unavailable | Commercial Changes / Commercial viability | 17/06/2025 |
| fluorouracil | Cream | 50 mg/g | Resolved | Available | Manufacturing | 17/06/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Current | Limited Availability | Manufacturing | 17/06/2025 |
| exemestane | Tablet, film coated | 25 mg | Resolved | Available | Manufacturing | 16/06/2025 |
| Vespula spp venom | Injection, powder for | 550 microgram | Current | Unavailable | Manufacturing | 16/06/2025 |
| solifenacin succinate | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 16/06/2025 |
| levothyroxine sodium | Tablet | .075 mg | Resolved | Available | Manufacturing | 16/06/2025 |
| terbinafine hydrochloride | Tablet, uncoated | 281.25 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/06/2025 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 16/06/2025 |
2025年6月23日